San Antonio Breast Cancer Symposium
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
Related Articles
Clive Peedell (@drpeedell.bsky.social)
Consultant Clinical Oncologist NHS advocate and campaigner Politically centre left Wealth inequality creates health inequality
Biomarker-Guided Treatment Approaches Transform Lung and GI Cancer Management
Experts across the fields of lung and GI cancer share key information and insights from 2 recent OncLive biomarker consortiums.
Ponsegromab for the Treatment of Cancer Cachexia | NEJM
Cachexia is a common complication of cancer and is associated with an increased risk of death. The level of growth differentiation factor 15 (GDF-15), a…
#ASH24: Treatments for R/R AML, maintenance strategies, and mutation- and MRD-informed decisions
Catch up with our live social media coverage of treatments for R/R AML, maintenance therapy, and mutation- and MRD-informed decisions from the 66th ASH Annual…
Non-T-depleted haploidentical transplantation in patients with secondary AML
Arnon Nagler, MD, Chaim Sheba Medical Center, Tel-Aviv, Israel, comments on the value of non-T-depleted haploidentical transplantation in patients with secondary acute myeloid leukemia (AML)…
FAST-Forward: safety of ultra-hypofractionated radiotherapy on cardiac health
Icro Meattini, MD, University of Florence, Florence, Italy, comments on the results of the FAST-Forward trial (ISRCTN19906132), stating that ultra-hypofractionated radiotherapy, as per the trial,…
Combinatorial strategies targeting NEAT1 and AURKA as new potential therapeutic options for multiple myeloma
Multiple myeloma (MM) is a dreadful disease, marked by the uncontrolled proliferation of clonal plasma cells (PCs) within the bone marrow (BM). MM is characterized…
IO-202 Plus Azacitidine Elicits Responses in HMA-Naive Chronic Myelomonocytic Leukemia
IO-202 plus azacitidine elicited an ORR of 66.7% in patients with HMA-naive chronic myelomonocytic leukemia.
Navtemadlin Reduces Spleen Size and Symptom Score in R/R Myelofibrosis
Navtemadlin monotherapy was safe and effective among patients with myelofibrosis who were relapsed or refractory to treatment with JAK inhibitors.